FDA, FTC put drugmakers on notice about tactics to block biosimilars

A joint agency meeting called out deceptive advertising and anti-competitive practices that may have kept the U.S. from catching up to Europe in establishing a market for lower-priced biologics.

FDA, FTC put drugmakers on notice about tactics to block biosimilars
A joint agency meeting called out deceptive advertising and anti-competitive practices that may have kept the U.S. from catching up to Europe in establishing a market for lower-priced biologics.